Harvard Bioscience, Inc. Q3 2026 Earnings Call Summary Moby Intelligence Tue, November 10, 2026 at 12:57 PM EST 4 min read NVDA -6.27% HBIO +0.11% Trade NVIDIA on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Revenue growth of 8% was primarily driven by strong demand from Contract Research Organizations (CROs) as biopharma customers increasingly outsource preclinical safety and efficacy monitoring.
The New Product Innovation (NPI) portfolio, specifically organoid and fluidics technologies, contributed over 11% of total revenue, reflecting a strategic alignment with the industry's shift toward human-relevant predictive data.
China revenue grew 31% year-over-year, supported by a localization strategy that now includes three fully available BTX electroporation product lines shipping in the region.
Gross margins were pressured by a shift in product mix toward lower-margin legacy products and increased volume through distribution partners, which management accepted to drive overall scale.
The revamped commercial team established a dedicated key accounts group to deepen relationships with top-tier pharmaceutical and biotech customers, leading to a doubling of sales through Fisher Scientific North America year-to-date.
Project Viking manufacturing consolidation remains on schedule, with the amino acid analyzer line successfully relocated to the Cambridge, U.K. facility and parallel builds starting for fluidics products.
Full-year 2026 revenue guidance of 3% to 5% growth is reaffirmed, supported by sustainable sales momentum in preclinical platforms and a strong Q4 outlook.
Adjusted EBITDA guidance was lowered to a range of negative 1% to 4% growth to reflect the continued impact of higher sales volumes from lower-margin legacy products and China shipments.
Project Viking is expected to deliver $3 million in net cost savings in 2027, scaling to $4 million annually thereafter, which will contribute directly to adjusted EBITDA and cash generation.
Management expects to launch a bioproduction version of its electroporation technology by mid-2027 to expand its addressable market beyond the research-focused sector.
Inventory levels are projected to decrease significantly following the completion of manufacturing transitions in Q1 2027, serving as a primary driver for improved balance sheet flexibility.
Project Viking restructuring charges and higher interest costs contributed to a shift from cash generation to cash use in operations through the first nine months of the year.
The company completed a 1-for-10 reverse stock split in March 2026, which is retroactively reflected in all per-share reporting for the quarter.
A newly formed Scientific Advisory Board held its inaugural meeting to guide the long-term technology roadmap and ensure alignment with emerging industry methodologies.
The academic funding environment in Europe and the U.S. remains a headwind, with management noting that any recovery in this sector would provide a significant tailwind to current growth.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
BTX saw strong double-digit growth year-to-date across all regions, primarily in the research sector rather than bioproduction.
Management believes they may be gaining market share but currently avoid direct competition with large bioproduction players until a GMP-approved product launches in mid-2027.
Approximately 75% of Project Viking's benefits are gross margin-related, primarily driven by manufacturing consolidation.
Management remains confident that these savings, combined with NPI growth, will move gross margins into the 60% range during 2027.
The academic market, representing roughly 40% of revenue, remains weak in both the U.S. and Europe, contributing to negative growth in the EMEA region.
Management is not assuming an NIH funding benefit in their current guidance, viewing any potential political shift in funding as a pure upside scenario.
The $3 million increase in inventory this year is a strategic move to support manufacturing prebuilds for Project Viking and ensure uninterrupted delivery during facility transitions.
These levels are expected to drop significantly once the transition concludes in Q1 2027, aiding cash flow recovery.
